Category: Trial Updates

Amazing news – drug seems to improve symptoms

Yesterday Ionis Pharmaceutical presented new data from their Huntingtin lowering trial, IONIS-HTTRx. The data demonstrates a relationship between reduction of the disease-causing  Huntingtin protein and improved symptoms for people with early stage Huntington’s Disease. After 3 months of treatment, the patients seems to benefit from the drug – now known as RG6042. This is very…
Read more

Wave partners with Takeda – HD research strengthened

The biotechnology company Wave Life Sciences strengthens their efforts in Huntington’s disease. In February they announced  their collaboration with Takeda, a Japanese pharmaceutical company with long and solid traditions.  The partnership enables Wave to continue their work in an even larger scale. The Japanese pharma company is listed with around 7000 employees and a paid…
Read more

Huntington News – now subtitled!

News and updates from the latest CHDI Therapeutics conferences have now been subtitled! In the video you can learn more about ongoing trials, stem cells, marijuana as treatment and HD-COPE. Click on the flag or find the video below and chose subtitles by clicking "CC" in the lower right corner. News from CHDI's Therapeutics Conferences

More positive data from the Ionis/Roche trial released today

Today Ionis and Roche have announced more details from the Huntingtin lowering trial.  The initial results was released in December last year and today at the CHDI conference in Palm Springs, more details from the trial results was presented.  The drug formely called IONIS-HTTRx  will from now on be named RG6042.  The drug was given…
Read more

Meeting with Roche

When the groundbreaking results of the Huntingtin lowering trial, IONIS-HTTRx, was announced the European Huntington Association travelled to Basel to meet Roche Pharmaceuticals. Roche have taken over the trial and is now planning the next step. Roche have put together their own team of around 20 people that are working on the Huntingtin lowering trial.…
Read more

Christmas card from Roche

This December IONIS Pharmaceuticals announced their groundbreaking results from the first Huntingtin lowering trial in humans (called IONIS-HTTRx). At the same time it was announced that Roche was going to take over the trial. Here is a message from their team: Dear members of the Huntington’s Community, We are delighted that IONIS-HTTRx is entering the…
Read more

Groundbreaking results!

This date will probably go into history along with the discovery of the Huntington gene in 1993. Today IONIS Pharmaceuticals announced the results from the first Huntingtin lowering trial in humans. The result exceeds all expectations. “I almost cried when I got the results,” Astri Arnesen the President of EHA, states. Best Christimas Gift ever…
Read more

Summer news from the HD community

Three times a year the EHDN newsletter appears. Now you can read the summer edition; with latest news from the Huntington’s Disease (HD) community!  If you are new to the European Huntington’s Disease Network, known as EHDN, it is a nonprofit research network with different aims: to advance research, facilitate clinical trials and improve clinical…
Read more

Spring News from the research community

Three times a year the EHDN newsletter appears. Now you can read the Spring edition – with latest news from the Huntington’s Disease (HD) research community. From page 8-10 you will find a interview with our own President, Astri Arnesen.  If you are new to the European Huntington’s Disease Network, known as EHDN, here’s a…
Read more

The World Orphan Drug Conference in Brussels

It was 300 attendees at the World Orphan Drug Conference in Brussels from the 16th to 17th of November. Among them was the European Huntington Association’s President Astri Arnesen, the Board Members Svein Olaf Olsen and Bea De Schepper.